Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin dose-ranging placebo-controlled study in drug-naive type 2 diabetes
2005-000473-22Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vildagliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novartis. Primary endpoint: Change from baseline in HbA1c at Week 24. Started Aug 2005; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-000473-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000473-22.